What's Happening?
Biogen is positioning itself to capture Alzheimer's patients transitioning off Eli Lilly's Kisunla therapy. As patients reach the 18-month mark of Kisunla treatment, Biogen is offering Leqembi as an alternative. Leqembi, which received FDA approval in January
2023, is part of a new wave of disease-modifying Alzheimer's treatments. Unlike Kisunla, which is dosed until amyloid plaques are cleared from the brain, Leqembi is administered indefinitely. This difference in dosing has posed regulatory challenges for Lilly, as their data only included patients on the drug for 12 months, affecting their approval process. Biogen's Leqembi has shown significant market growth, with a 74% increase in sales year-over-year, reaching $168 million globally in Q1 2026. The company is also awaiting FDA approval for a subcutaneous version of Leqembi, which could further enhance its market position.
Why It's Important?
The transition of Alzheimer's patients from Kisunla to Leqembi highlights the competitive landscape in the Alzheimer's treatment market. Biogen's strategic positioning could significantly impact its market share and financial performance. The indefinite dosing of Leqembi offers a potential advantage over Kisunla, which may influence physician and patient preferences. This shift could also affect Eli Lilly's market position, as Biogen's alternative may appeal to patients and healthcare providers seeking long-term treatment options. The outcome of Biogen's FDA approval for the subcutaneous version of Leqembi could further disrupt the market dynamics, potentially removing Kisunla's dosing advantage.
What's Next?
Biogen is awaiting a decision from the FDA on May 24 regarding the approval of the subcutaneous version of Leqembi for induction use. If approved, this could enhance Biogen's competitive edge by offering a more convenient at-home treatment option. The healthcare community is closely monitoring this development, as it could influence treatment protocols and patient management strategies. Additionally, Biogen's continued efforts to improve the care pathway and address reimbursement issues will be crucial in maintaining and expanding its market share.
